ZielBio
Charlottesville
About ZielBio
ZielBio is an early-stage biotechnology company that identifies novel high-value disease targets and develops therapeutic interventions to improve patient outcomes. Its proprietary drug discovery platform Zielfind combines the power of functional, high throughput screening with large content data analytics to identify high-value targets. They have a promising pipeline of therapies and targets, including lead compound ZB131, a proprietary humanized monoclonal antibody against cell surface plectin (CSP) a cancer target identified through Zielfind. ZielBio was founded in 2011 and is based in Charlottesville, Virginia, United States.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $33.0M
- Last round: Series Unknown (Sep 2022)
- Website: zielbio.com
- Phone: (434) 202-7771
Industries & Categories
Biotechnology, Health Care, Therapeutics
Canonical: https://fsome.com/organization/zielbio-53256 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.